Tumor Escape
-
Subject Areas on Research
- A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy.
- Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
- Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.
- Autologous tumor rejection in humans: trimming the myths.
- Bispecific antibodies engage T cells for antitumor immunotherapy.
- CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
- Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.
- Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
- Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
- Gold nanoparticles-mediated photothermal therapy and immunotherapy.
- Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.
- Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation.
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
- Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.
- Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
- Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
- Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
- STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
- Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.
- The Evolving Modern Management of Brain Metastasis.
- The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
- Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
- cDNA arrays and the enigma of melanoma immune responsiveness.
-
Keywords of People
- Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
- Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology